Market Overview

UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name

Share:
Related LLY
Who Is The Former Pharma Exec Trump Nominated To Lead HHS?
Stocks Going Ex Dividend The Third Week of November
Lilly to release 2018 guidance December 13 (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated an Underperform rating on Eli Lilly & Co. (NYSE: LLY), and slightly raised the price target from $43.00 to $44.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Eli Lilly & Co. closed on Tuesday at $56.74.

Latest Ratings for LLY

DateFirmActionFromTo
Oct 2017Leerink SwannMaintainsMarket Perform
Oct 2017BarclaysMaintainsOverweight
Oct 2017BMO CapitalMaintainsUnderperform

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

View Comments and Join the Discussion!

Partner Center